Lilly snaps up Ventyx for $1.2B in pursuit of oral immune drugs [Yahoo! Finance]
Ventyx Biosciences, Inc. (VTYX)
Company Research
Source: Yahoo! Finance
Eli Lilly is deepening its investment in inflammatory diseases, spending $1.2 billion to buy Ventyx Biosciences for an experimental drug that has the potential to treat an array of immunological conditions. The Indiana-based manufacturer of obesity drug Zepbound announced Wednesday it will spend $14 per share to buy Ventyx, which in October reported promising data for an oral immune disease drug code-named VTX3232. The per-share figure represents a 62% premium to Ventyx's average trading price for the 30 days ending Jan. 5. News of the pending acquisition was first reported by the Wall Street Journal on Tuesday, sending shares close to the value Lilly ultimately paid. Ventyx's drug is part of a class of medications that Lilly doesn't have. Known as NLRP3 inhibitors, these drugs block proteins that stimulate inflammation in a variety of tissues, making them potentially helpful in treating cardiometabolic, neurological and immunological disorders. In October, for instance, Vent
Show less
Read more
Impact Snapshot
Event Time:
VTYX
Last Price
Price Change
Price Change%
Volume Shares
Max Up
Max Down
%
Volume Ratio
Performance Comparison
Updated
|
Event Day
Stock performance from the time of news release until the following 4pm ET market close
|
Last price at news event
|
Since Event
Multi-day stock performance from the time of the news release
|
|---|---|---|
|
EVENT DAY
Stock performance from the time of news release until the following 4pm ET market close
|
LAST
PRICE AT NEWS EVENT |
SINCE EVENT
Multi-day stock performance from the time of the news release
|
| Last Price | ||
| VWAP | ||
|
High:
|
Max Up |
High:
|
|
Low:
|
Max Down |
Low:
|
|
%
|
Post news range |
%
|
|
|
Price change |
|
|
|
Price Change Percentage |
|
|
|
S&P 500 (SPX) |
|
|
%
|
Volume ratio |
%
|
| Volume | ||
| Ticks | ||
|
|
Avg transaction size |
|
Don't Miss Out On The Next BIG Stock Move
Event day
Event Day Chart will not be displayed beyond 90-day period of the event
Performance since event
Time And Velocity Analysis
Be the first to know
Opt in for alerts from News Quantifed
Sign Up Today
Opt-in for
VTYX alerts
Learn More With NQ
Reading the Impact Report
Help Me Understand This Data
Help Me Understand This Data
How NQ Works
What is news-based trading?
And why is it so successful?
And why is it so successful?
Movers & Shakers
The biggest gainers and losers and WHY it moved
VTYX alerts
High impacting Ventyx Biosciences, Inc. news events
Weekly update
A roundup of the hottest topics
VTYX
News
- INVESTOR ALERT: Pomerantz Law Firm Investigates Claims On Behalf of Investors of Ventyx Biosciences, Inc. - VTYXGlobeNewswire
- Eli Lilly and Company (LLY) to Acquire Ventyx Biosciences [Yahoo! Finance]Yahoo! Finance
- Ventyx Biosciences (NASDAQ:VTYX) was downgraded by analysts at UBS Group AG from a "strong-buy" rating to a "hold" rating.MarketBeat
- Ventyx Biosciences (NASDAQ:VTYX) was downgraded by analysts at Wells Fargo & Company from a "strong-buy" rating to a "hold" rating.MarketBeat
- Ventyx Biosciences (NASDAQ:VTYX) was downgraded by analysts at Clear Str Llc from a "strong-buy" rating to a "hold" rating.MarketBeat
VTYX
Earnings
- 11/6/25 - Beat
VTYX
Sec Filings
- 1/9/26 - Form SCHEDULE
- 1/9/26 - Form SCHEDULE
- 1/8/26 - Form DEFA14A
- VTYX's page on the SEC website